What Emervax does

Emervax is a privately held, Houston-based biotechnology company and spin-out from the University of Texas Medical Branch in Galveston that is developing a proprietary circular RNA (circRNA) vaccine platform branded emxRNA™. The platform's closed-loop RNA architecture is designed to provide greater stability and durability of protein/antigen production than conventional linear mRNA vaccines, and is combined with a proprietary RNA purification process and thermostable nanoparticle delivery that together enable room-temperature storage and multi-antigen incorporation across infectious disease, oncology, and autoimmune indications.

The company's pipeline is anchored on two vaccine programs: a Yellow Fever Virus (YFV) candidate positioned as safer for immunocompromised and elderly populations than the existing YFV-17D vaccine, and a Hantaan Virus (HTNV) candidate addressing Haemorrhagic Fever with Renal Syndrome, a disease with roughly 15% fatality and no commercial vaccine. Emervax is enhancing its core platform through two exclusive delivery partnerships: a worldwide license to Certest Biotec's thermostable lipid nanoparticle technology (up to four weeks of liquid stability at room temperature) and an exclusive license to Kindeva Drug Delivery's solid-coated microneedle array patch for simplified intradermal administration, with clinical trials anticipated in 2026.

The company is pre-revenue and operates a B2B model, currently funded by non-dilutive grants from CEPI (up to $2.15 million, October 2023) and the UK SBRI/UK Vaccine Network (approximately £1.7 million, January 2024). Future revenue is expected to flow from licensing agreements, pharmaceutical and CDMO partnerships, and eventual commercial vaccine sales, serving global health/infectious disease prevention as the primary segment, with cancer therapeutics and autoimmune disorders as secondary verticals.

Name

Emervax

Legal name

Emervax Inc.

Website

https://emervax.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Emervax is a Houston-based biotech and UTMB Galveston spin-out developing a proprietary circular RNA (emxRNA™) vaccine platform for emerging viruses, cancer, and autoimmune disorders. Pre-revenue, funded by CEPI and SBRI grants, with clinical trials anticipated in 2026.

Ownership category

akta.pro rank

Product category

Vaccine Development / Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Circular RNA vaccines
• RNA vaccine platform
• Infectious disease vaccines
• Vaccine technology licensing
• Thermostable vaccines

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Vaccine Development and Licensing: Pre-revenue biotech company focused on developing proprietary circular RNA vaccine platform. Revenue expected through licensing agreements, partnerships, and eventual commercial vaccine sales. Currently funded by CEPI and NIH grants.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

Emervax is developing a proprietary circular RNA (circRNA) vaccine platform called emxRNA™ for the prevention and control of emerging viruses and chronic diseases. The core platform combines circular RNA technology with proprietary purification methods, thermostable lipid nanoparticle formulations, and a co-developed microneedle array patch delivery system. Pipeline programs include Yellow Fever Virus (YFV) and Hantaan Virus (HTNV) vaccine candidates, with clinical trials anticipated in 2026.

Product overview

Emervax is a biotechnology company and University of Texas Medical Branch spin-out that has developed a proprietary circular RNA-based vaccine platform called emxRNA™. This core platform comprises circular RNA technology with proprietary sequences for high-efficiency circularization and significant protein production, combined with advanced purification methods and innovative delivery strategies. The platform is enhanced by two key delivery partnerships: the Thermostable LNP Platform from Certest Biotec for room-temperature storage (up to four weeks in liquid form) and the Microneedle Array Patch Delivery System from Kindeva Drug Delivery for simplified intradermal administration. The company is deploying this modular platform across two pipeline programs: the Yellow Fever Virus (YFV) Vaccine Program and the Hantaan Virus Vaccine Program. The platform targets high-growth markets in infectious diseases, cancer therapeutics, and autoimmune disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• emxRNA™ Platform A proprietary circular RNA (circRNA) vaccine technology platform offering superior stability, longevity, and immune response compared to traditional linear mRNA vaccines. The closed-loop structure is less susceptible to degradation, supports increased durability of protein production, and enables improved efficacy at lower doses.
• Yellow Fever Virus (YFV) Vaccine Program Pipeline vaccine candidate designed to offer safe and long-lasting immune response against Yellow Fever Virus for all populations, including immunocompromised and elderly individuals who are at risk with the current YFV-17D live-attenuated vaccine.
• Hantaan Virus Vaccine Program Pipeline vaccine candidate targeting Hantaan virus (HTNV), responsible for Haemorrhagic Fever with Renal Syndrome (HFRS), addressing unmet medical need given the lack of any current commercial vaccine and high fatality rate of approximately 15%.
• Microneedle Array Patch Delivery System Solid-coated microneedle array patch technology licensed exclusively from Kindeva Drug Delivery for accurate and reliable intradermal delivery of emxRNA vaccines. Enables pain-free administration, at-home dosing potential, and improved stability profile reducing cold chain requirements.
• Thermostable Lipid Nanoparticle (LNP) Platform Ionizable lipid-based nanoparticle technology licensed exclusively worldwide from Certest Biotec that enables room-temperature stability for up to four weeks in liquid form, eliminating the need for ultra-cold storage required by traditional mRNA vaccines.

Quantifiable outcome

• Increased durability of protein/antigen production in the body after administration, potentially resulting in improved efficacy with lower doses
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core, major and supporting.

• Certest BioteccoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Exclusive global licensing agreement where Certest's proprietary thermostable lipid nanoparticle (LNP) platform powers Emervax's emxRNA vaccine formulations. Certest's ionizable lipid-based nanoparticles enable room-temperature stability for up to four weeks in liquid form, eliminating ultra-cold storage requirements.
• Kindeva Drug DeliverycoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Exclusive partnership to co-develop microneedle array patch for administration of emxRNA vaccines targeting emerging viruses. Kindeva grants exclusive license to use its solid-coated microneedle array patch technology. Solution minimizes cold chain storage needs and simplifies administration. Joint offering anticipated to move into clinical trials in 2026.
• EnsiliTechcoreTechnology or Integration · 1 January 2024Partnership to develop world's first thermally stable mRNA vaccine against Hantaan Virus. EnsiliTech awarded approximately £1.7 million SBRI research contract. Project in partnership with Afrigen Biologics in South Africa and Emervax in the US. EnsiliTech's ensilication technology removes the need for cold storage.
• Afrigen BiologicsmajorStrategic or Co-development Partner · 1 January 2024South African partner in the SBRI-funded project for thermally stable mRNA Hantaan vaccine. Afrigen's priority is to make mRNA vaccines accessible and affordable to low- and middle-income countries, eliminating or reducing cold chain logistics needs.
• S-cubed LtdsupportingImplementation/ SI/ Consulting Partner · 1 January 2024Regulatory Affairs Consultancy support for the SBRI-funded thermally stable mRNA Hantaan vaccine project.

Scale indicators3 records

Recent moves5 records

Expansion highlights8 records

Broad incumbents

• Novavax: Clinical-stage vaccine company with an approved protein subunit COVID-19 vaccine and pipeline targeting infectious diseases with unmet need. Overlaps with Emervax on infectious disease vaccine positioning and global health distribution focus.
• Moderna: Established mRNA vaccine leader with approved COVID-19 vaccine and a broad pipeline spanning infectious disease, oncology, and rare disease. Operates in the same RNA vaccine space as Emervax at vastly greater scale and capitalization.
• CureVac: Pioneer mRNA therapeutics company developing vaccines and oncology therapies using optimized mRNA constructs and proprietary lipid carriers. Closely comparable technology category to Emervax with a longer clinical history.
• Emergent BioSolutions: Specialty biopharmaceutical company focused on vaccines and therapeutics for public health threats, with significant pandemic preparedness and government contracting footprint. Comparable as a counterparty/scale competitor in outbreak-response vaccines.
• BioNTech: Major mRNA vaccine company with an approved COVID-19 vaccine (with Pfizer), extensive infectious disease and oncology pipeline, and large investments in next-generation RNA formats. Same product category as Emervax.

Direct peers

• Arcturus Therapeutics: Clinical-stage developer of self-amplifying mRNA and conventional mRNA vaccines with proprietary LNP delivery technology. Closely comparable to Emervax's emxRNA + thermostable LNP + microneedle stack and already in vaccine clinical development.
• Orna Therapeutics: Cambridge-based biotech developing circular RNA (oRNA) therapeutics for oncology and infectious disease. Direct competitor to Emervax's circRNA vaccine platform with comparable mechanism and earlier disclosed pipeline.
• Sail Biomedicines: Pioneer in circular RNA therapeutics, formed from the merger of Laronde and Senda Biosciences. Directly comparable as a circRNA platform pursuer with broader therapeutic-area ambition and substantial prior funding.

Emerging players

• Vaxxas: Developer of a high-density microarray patch (HD-MAP) for needle-free vaccine delivery. Functionally comparable to Emervax's Kindeva-licensed microneedle partnership and a likely alternative delivery platform for next-gen RNA vaccines.
• Kernal Biologics: Developer of mRNA therapeutics specifically for oncology and autoimmune indications, with selective mRNA translation technology. Comparable to Emervax's stated oncology and autoimmune therapeutic area expansion plans.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/emervaxinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emervax